CONFERENCE DAY ONE
8:00 am Check-In & Light Breakfast
8:50 am Chair’s Opening Remarks
From the Lessons Learnt to Strategic Partnerships: Establishing the Roadmap Towards Novel & Synergistic Cancer Immunotherapy Combinations
9:00 am Navigating the Maze: Challenges & Strategies for Combination Immunotherapies in Early-Phase Clinical Trials
Synopsis
• Achieving impressive monotherapy efficacy in late lines/post PDx pts has a very low likelihood
• The true value of an IO agent resides in adding clinical benefit on top of standard of care or rational combo with new agents
• How to select and assess cancer immunotherapy combinations in early-phase clinical studies (based upon rational mechanism of action concurrent to standard of care landscape (bolt – on , 3 vs 2, etc.)
9:30 am Panel Discussion: Shaping the Future of Cancer Immunotherapy Combinations with Strategic Partnerships & Collaborations to Bring Precise & Effective Treatments to Patients
Synopsis
• How to successfully identify complimentary immuno-oncology platforms such as adoptive cells, Bispecific T cell engagers, oncolytic viruses and beyond to discover and develop novel and life-saving cancer immunotherapy combinations?
• How to overcome challenges such as stakeholder management, funding and resource to provide a wide range of cancer patients with improved access to treatment options?
• What are the key economical, commercial and market access considerations to have as early as possible to avoid failures or delays in the future?
10:00 am Morning Break & Speed Networking
Synopsis
This is your opportunity to get face to face with some of the brightest minds in immune-oncology to connect and establish meaningful business relationships.
Improving Response Rate & Durability of Your Drugs Through Rational & Synergistic Combination Strategies
11:00 am Cancer Immunotherapy Combined with ADCs: Exploiting Novel & Rational Combinations
Synopsis
• Combining cancer immunotherapy with ADCs: Independent action verses synergy
• Cancer immunotherapy combined with ADCs: Combinations based on efficacy response
• Does adding in chemotherapy provide additional benefit to cancer immunotherapy combined with ADC’s?
11:30 am Biovian Session Details to be Confirmed
11:40 am Rational Combinations to Enhance Efficacy of Bispecific T Cell Engagers (BiTEs) in Solid Tumors
Synopsis
• Recent progress with development of bispecific T-cell engager (BiTE) molecules in solid tumors
• Strategies to improve response rate and durability
• Preclinical data for the DLL3-targeted BiTE molecule (IMDELLTRA™ / tarlatamab) in combination with standard of care and Immune check point inhibitors, and translation to the clinic
12:10 pm Harnessing Synergy: Multi-Modal Approaches to Enhance CAR T-Cell Therapy in Multiple Myeloma
Synopsis
• CAR-T cell therapy in multiple myeloma is currently not curative; an exhausted and immunosuppressive microenvironment contributes to resistance and relapse
• Immunomodulatory agents activate T and NK cells as monotherapy and could be used to extend responses with limited downside
• Multimodal treatment strategy can be applied to T cell-engaging therapies more broadly
12:40 pm Lunch & Networking Break
Overcoming Complex Cancer Biology with Novel Multimodal Combinations Beyond Traditional Checkpoint Inhibitors
1:40 pm Prime-Boost: Oncolytic Virotherapy in Combination with Tumor Vaccines for Durable Anti-Tumor Immunity
Synopsis
• How oncolytic virotherapy can alter TME to create a favorable immune environment for secondary therapeutic targeting
• How tumor cell lysis releases entire spectrum of tumor neoantigens and expands TCR repertoire for broader antigen recognition by the immune system in preparation for vaccine administration
• How the prime-boost regime can create a durable anti-tumor response to combinations of virotherapy with tumor vaccines
2:10 pm TNF Alpha & IL-2 Expressing Oncolytic Adenovirus to Enable T-cell Therapies
Synopsis
• How using an oncolytic virus can overcome some of the limitations of T-cell therapy
• How the treatments induce immune changes in tumor and blood of patients
• How the approach results in immunotherapy naïve patients vs those that progressed upon immunotherapy
2:40 pm Afternoon Break & Poster Session
Reducing Toxicity Whilst Improving Potency Through Effective Patient Selection, Protocol Design & Dosage Optimization
3:30 pm A Landscape Analysis of Oncolytic Virus Therapies & Combination Therapies
Synopsis
• Exploring the preclinical landscape of oncolytic virotherapies, highlighting key developers
• Analysing the clinical landscape, highlighting key combination therapies used in trials and the relevant drug developers
• Outlining key regulatory announcements or deals, especially for combination trials, and examining the future outlook of the oncolytic virus field
4:00 pm Improving Potency & Reducing Toxicity; Combining T cell Engagers with DiakinesTM
Synopsis
• DiakinesTM independently accumulate in the T cell synapse, enhancing T cell avidity for tumor cells
• DiakinesTM independently stimulate and enhance T cell function and permit the same
100% cytotoxicity with 1 – 2 logs less T cell engager concentrations
• DiakinesTM combinatorically suppress CRS stimulated by T cell engagers by controlling cytokines secreted by T cells, and controlling CRS associated cytokine secretion from monocytes
4:30 pm VAX014 Co-Delivers STING/RIG-I Agonists with a Novel Oncolytic Mechanism to Facilitate Robust in situ Immunization Prior to Systemic Checkpoint Blockade
Synopsis
• How VAX014, a novel tumor-targeted oncolytic agent based on recombinant bacterial minicells can facilitate in situ immunization
• Nonclinical data to support VAX014's ability to function optimally in STING/RIG-I positive tumors
• Nonclinical data to show that VAX014 in combination with immune checkpoint inhibitors gives additive benefit in the treatment of solid tumors
5:00 pm TCR like Condensate Signaling in Intrinsically Disordered Regions Forms Microsynapses & Shows Increased Potency Against Solid Tumors and is Amenable to Combination Therapy With ICIs and mRNA CAR Antigen Vaccines
Synopsis
• IDR domains in CAR receptors induce phase separation and TCR like condensate formation, signaling and microsynapse formation
• Microsynapse formation is expected to increase PD-1 and CD28 in the immune synapse and hence sensitize to PD-1 checkpoint blockade
• mRNA CAR antigen vaccines can actívate and expand IDR-CAR-T cells to show increased persistence. Tumor killing by IDR-CAR-T cells can increase antigen presentation and activation of endogenous immunity